---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-060822"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T13:50:10.289538+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q1 2022 net loss $5.4M, cash $18.4M; progresses NurOwn ALS program

## Summary
- Net loss $5.4M ($0.15/sh) improved from $6.7M ($0.19/sh) in Q1 2021.
- Cash $18.4M at Mar 31, down from $22.1M at Dec 31, 2021.
- R&D spend cut to $2.6M from $4.3M; G&A rose to $2.9M from $2.6M.
- Presented Phase 3 NurOwn biomarker data at AAN 2022; genetic analysis at MDA conference.
- Appointed Netta Blundheim-Shraga as VP R&D and Antal Pearl-Lendener as Chief Legal Counsel.

## SEC filing metadata
- accession: 0001104659-22-060822
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/0001104659-22-060822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/tm2215644d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-060822
- JSON: https://secwatch.observer/filing/0001104659-22-060822.json
- Plain text: https://secwatch.observer/filing/0001104659-22-060822.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported first quarter ended March 31, 2022 results: net income approximately $5.4 million, EPS $0.15.
  - Period: first quarter ended March 31, 2022
  - Net income: approximately $5.4 million
  - EPS: $0.15
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2022, was approximately $5.4 million, as compared to a net loss of approximately $6.7 million for the three months ended March 31, 2021. Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/0001104659-22-060822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.